Previous close | 236.08 |
Open | 254.72 |
Bid | 253.19 x 800 |
Ask | 253.54 x 900 |
Day's range | 249.59 - 255.67 |
52-week range | 182.09 - 259.00 |
Volume | |
Avg. volume | 2,692,035 |
Market cap | 187.446B |
Beta (5Y monthly) | 0.86 |
PE ratio (TTM) | 44.88 |
EPS (TTM) | 5.64 |
Earnings date | 23 Apr 2024 |
Forward dividend & yield | 1.08 (0.46%) |
Ex-dividend date | 27 Mar 2024 |
1y target est | 249.35 |
While Danaher (DHR) surpasses first-quarter earnings and revenue estimates, its performance is hurt by a decrease in core sales in the Biotechnology segment.
The medical company reports first-quarter adjusted earnings of $1.92 a share, beating Wall Street estimates of $1.72.
Although the revenue and EPS for Danaher (DHR) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.